Heron Therapeutics (HRTX) Misses Q3 EPS by 9c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.10), $0.09 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $38.2 million versus the consensus estimate of $39.49 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• TD Cowen Starts Braveheart Bio (BRVE) at Buy
• Cloudflare (NET) Reiterated at Market Outperform by Citizens After Meeting With CFO, AI Head
• KKR & Co. (KKR) call put ratio 2.4 calls to 1 put